Supplementary Figures 4B, 5B, 6B depict the SCNA status of METTL14, ZC3H13, and YTHDC1 in diverse cancer types. The outcome module indicated the relevance of infiltrating immune subsets to tumor clinical stage (Figures 4D, 5D, 6D). Spearman analysis revealed that, in various cancers, the expression of METTL14, ZC3H13, and YTHDC1 was positively correlated with programmed death-ligand 1 (PD-L1) expression (Figure 7A). The same was observed for EC (Figure 7B). This evidence concerns the gene METTL14 and cancer.